BMJ:治疗2型糖尿病,二甲双胍与磺脲类药物联用比单独用药更安全

2018-07-21 佚名 medicalxpress

发表在《英国医学杂志》上的一项研究发现,对于2型糖尿病患者来说,使用磺酰脲类药物来控制血糖水平与使用二甲双胍相比,会增加并发症的风险。

发表在《英国医学杂志》上的一项研究发现,对于2型糖尿病患者来说,使用磺酰脲类药物来控制血糖水平与使用二甲双胍相比,会增加并发症的风险。

因此,研究人员表示,在引入磺脲类药物时,继续使用二甲双胍比切换更安全。

二甲双胍是一种治疗2型糖尿病的“一线”疗法(第一种将要尝试的药物)。但磺脲类药物是最常用的“二线”治疗方法,常与二甲双胍联合使用。

磺脲类药物的安全性已被广泛研究。然而,与单独使用二甲双胍治疗相比,添加或切换到磺脲类药物的具体风险却鲜为人知。

因此,由加拿大麦吉尔大学的萨米·苏伊萨教授领导的一个研究小组,开始评估是否增加或转向磺脲类药物会增加患严重并发症的风险,而在2型糖尿病患者中仅使用二甲双胍的风险就会增加。

他们分析了英国临床实践研究数据链在1998年至2013年间开始二甲双胍治疗的77,000名2型糖尿病患者(平均年龄64岁)的数据。

随后添加或转换到磺脲类药物的患者被识别并与一个单独使用二甲双胍的病人相匹配。

然后,医院记录被用来监测心脏病发作(心肌梗死)、缺血性中风、心血管死亡、任何原因的死亡(“所有原因导致死亡”)和危险的低血糖水平(严重低血糖)的入院情况。

在一年多一点的平均随访期内,使用磺脲类药物(转换和添加联合用药)会增加心脏病发作的风险(每1000人每年7.8 v 6.2次),所有这些都会导致死亡率(27.3 v 21.5次)和严重低血糖(5.5 v 0.7次),而仅仅使用二甲双胍就会增加。

使用磺脲类药物也有增加缺血性卒中(每1000人6.7 v 5.5)和心血管死亡(9.4 v 8.1)风险的趋势。

与在二甲双胍治疗中加入磺脲类药物相比,改用磺脲类药物可增加心脏病发作的风险和所有原因的死亡率,但缺血性卒中、心血管死亡或严重低血糖均无差异。

在进一步的分析后,结果仍然相似,以测试结果的强度。

这是一项观察性研究,因此无法确定因果关系,研究人员说,他们不能排除某些观察到的风险可能是由其他未测量的(混杂的)因素造成的可能性。尽管如此,他们说他们的结果是高度一般化的,并且大的样本容量允许计算精确的估计。

因此,他们得出的结论是,磺脲类药物作为二线药物“与二甲双胍单一治疗相比,与增加心肌梗死的风险、所有原因的死亡率和严重的低血糖有关”。

他们补充说,重要的是,与心肌梗死和所有原因死亡的关联“是由使用磺脲类药物而不是添加磺脲类药物引起的”。“因此,按照目前关于治疗2型糖尿病的建议,在引入磺脲类药物时,继续使用二甲双胍比改用二甲双胍更安全。”

美国研究人员Lucy D'Agostino McGowan和Christianne Roumie在一篇相关的社论中说,这一新的证据有助于将治疗决策个性化,并将危害降至最低。

他们指出,很难根据观察性研究来定义临床实践,因为使用不同疗法的患者可能在无法测量的方面存在差异。然而,他们说,这项研究“设计得很好,而且它们之间的关系看起来很牢固和一致。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848564, encodeId=4ea318485640a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 11 01:51:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442160, encodeId=0321144216060, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511857, encodeId=7967151185e6a, content=<a href='/topic/show?id=ad038e8524b' target=_blank style='color:#2F92EE;'>#药物联用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87852, encryptionId=ad038e8524b, topicName=药物联用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427910383520, createdName=751943081_32627952, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041723, encodeId=1f251041e2326, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 21 19:51:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333202, encodeId=67b333320278, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 21 19:31:16 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333186, encodeId=2728333186d1, content=联合用药优点多多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jul 21 17:27:57 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-10-11 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848564, encodeId=4ea318485640a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 11 01:51:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442160, encodeId=0321144216060, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511857, encodeId=7967151185e6a, content=<a href='/topic/show?id=ad038e8524b' target=_blank style='color:#2F92EE;'>#药物联用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87852, encryptionId=ad038e8524b, topicName=药物联用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427910383520, createdName=751943081_32627952, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041723, encodeId=1f251041e2326, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 21 19:51:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333202, encodeId=67b333320278, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 21 19:31:16 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333186, encodeId=2728333186d1, content=联合用药优点多多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jul 21 17:27:57 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1848564, encodeId=4ea318485640a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 11 01:51:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442160, encodeId=0321144216060, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511857, encodeId=7967151185e6a, content=<a href='/topic/show?id=ad038e8524b' target=_blank style='color:#2F92EE;'>#药物联用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87852, encryptionId=ad038e8524b, topicName=药物联用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427910383520, createdName=751943081_32627952, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041723, encodeId=1f251041e2326, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 21 19:51:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333202, encodeId=67b333320278, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 21 19:31:16 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333186, encodeId=2728333186d1, content=联合用药优点多多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jul 21 17:27:57 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1848564, encodeId=4ea318485640a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 11 01:51:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442160, encodeId=0321144216060, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511857, encodeId=7967151185e6a, content=<a href='/topic/show?id=ad038e8524b' target=_blank style='color:#2F92EE;'>#药物联用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87852, encryptionId=ad038e8524b, topicName=药物联用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427910383520, createdName=751943081_32627952, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041723, encodeId=1f251041e2326, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 21 19:51:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333202, encodeId=67b333320278, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 21 19:31:16 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333186, encodeId=2728333186d1, content=联合用药优点多多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jul 21 17:27:57 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-21 misszhang

    谢谢MedSci提供最新的资讯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1848564, encodeId=4ea318485640a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 11 01:51:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442160, encodeId=0321144216060, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511857, encodeId=7967151185e6a, content=<a href='/topic/show?id=ad038e8524b' target=_blank style='color:#2F92EE;'>#药物联用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87852, encryptionId=ad038e8524b, topicName=药物联用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427910383520, createdName=751943081_32627952, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041723, encodeId=1f251041e2326, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 21 19:51:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333202, encodeId=67b333320278, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 21 19:31:16 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333186, encodeId=2728333186d1, content=联合用药优点多多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jul 21 17:27:57 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-21 天地飞扬

    了解一下,谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1848564, encodeId=4ea318485640a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 11 01:51:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442160, encodeId=0321144216060, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511857, encodeId=7967151185e6a, content=<a href='/topic/show?id=ad038e8524b' target=_blank style='color:#2F92EE;'>#药物联用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87852, encryptionId=ad038e8524b, topicName=药物联用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427910383520, createdName=751943081_32627952, createdTime=Mon Jul 23 07:51:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041723, encodeId=1f251041e2326, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 21 19:51:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333202, encodeId=67b333320278, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 21 19:31:16 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333186, encodeId=2728333186d1, content=联合用药优点多多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jul 21 17:27:57 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-21 1e0f8808m18(暂无匿称)

    联合用药优点多多。

    0

相关资讯

健康肥胖”可能不增加2型糖尿病风险

诸多研究证实了肥胖是2型糖尿病(T2DM)的危险因素,然而有趣的是,并不是所有肥胖者的T2DM风险都会升高。近期中国一项研究表明,白细胞(WBC)计数可作为判断肥胖是否会导致T2DM风险增加的指标。那么,为什么选择WBC计数?如何通过WBC计数预测肥胖对于T2DM风险的影响?如何解释WBC计数与T2DM风险的相关性?这一发现有什么临床意义?下面我们将对这些问题进行逐一探讨。

Diabetic Med:Roux-en-Y胃旁路术和袖状胃切除术后对2型糖尿病的作用?

近日,国际杂志 《Diabetic Med》上在线发表一项关于Roux-en-Y胃旁路术和袖状胃切除术后2年缓解2型糖尿病-比较DiaRem和DiaBetter评分和减重的作用的研究。 Roux-en-Y胃绕道手术(RYGB)和袖状胃切除术对缓解2型糖尿病和体重减轻作用的比较疗效尚不清楚。本研究的目的是比较DiaRem和DiaBetter评分,包括糖尿病持续时间,在RYGB和袖状胃切除术后2

Lancet Diabetes Endo:2型糖尿病患者 强化降压将危害肾脏

很多指南目前都推荐强化降压,更是对2型糖尿病患者推荐要严格的控制血压(包括2017年美国心脏病学会和美国心脏协会血压指南)。但强化降压真的适用于所有患者吗?

Diabetic Med:2型糖尿病智力残疾成人的特征如何?

近日,国际杂志 《Diabetic Med》上在线发表一项关于2型糖尿病智力残疾成人表征的病例发现研究的结果。该报告是对有轻度至中度智力障碍2型糖尿病的成年人进行支持性自我管理干预的可行性试验期间,进行的病例研究结果,根据糖尿病控制、健康状况描述研究样本的特征,并寻找糖尿病管理服务和支持的方法。 研究人员在英国(2013年3月至2015年6月)进行了一项横截面病例调查研究,主要通过初级保健机

JACC:SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险?

使用口服抗凝药(OACs)进行卒中预防是房颤管理的基础。然而,年龄≥90岁的患者使用OACs的数据有限。2018年7月,发表于《Circulation》上的一项队列研究,考察了OACs对老老年房颤(AF)患者的影响。

Hypertension:强化血压治疗可降低标准控制血糖的2型糖尿病患者的心血管事件风险

强化血压(BP)治疗是否有助于预防心血管事件,包括2型糖尿病患者的心衰?现有学者对此展开研究。研究人员利用ACCORD BP试验的数据,根据Cox风险率模型计算心血管事件的风险比,对比采取标准疗法(2362人)和强化血糖控制(2371人)的患者首次发生心血管事件的时间。总体平均随访4.5年,随访期间有528位患者确诊发生心血管事件。对于采用标准血糖控制的患者,强化BP治疗组的心血管事件风险明显低于